Kedudukan dalam Saham
#27070
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Harga Saham
$2.04
Disegerakkan terakhir: 2025-12-09
Perubahan (1 tahun)
-2.39%
Perdagangan Mural Oncology plc (MURA)
Harga MURA dengan permodalan pasaran b
Modal pasaran bagi Mural Oncology plc(MURA)
Modal Pasaran: $35.38M
Sehingga August 2026, Mural Oncology plc mempunyai modal pasaran sebanyak $35.38M. Ini menjadikan Mural Oncology plc syarikat ke-27070th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Mural Oncology plc dari 2023 hingga 2026
MURA berbanding dengan 5 teratas yang paling popular stocks
| Harga MURA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.301T
|
+14,980,430.71%
|
|
|
|
|
$4.634T
|
+13,095,454.05%
|
|
|
|
|
$4.143T
|
+11,708,180.82%
|
|
|
|
|
$3.589T
|
+10,143,655.51%
|
|
|
|
|
$2.857T
|
+8,073,786.56%
|
